top of page
.png){kind=small}
RESEARCH
TT-01
Features:
Novel immune epitopes.
Pipeline
Pre-Clinical
Pre-Clinical
TT-01
Antibody-Drug Conjugates
(TT-01 ADC)
Features:
The TT-01 ADC has due functions, the first is relieve the T cell inactivation, the second is antibody internalized into tumor cells. Combine two functions to induce tumor killing effect.
TOP-108
.jpg)
CAR-108
CAR-T Cell Therapy
Features:
The CAR-T cell therapy was developed using the TT-01 sequence that can accurately identify glycosylated antigen as a template.
In the cell-based experiments, it has been proven that CAR-108 can kill 80% of tumor cells effectively.
In the in vivo animal study, the tumor was totally remission after CAR-T treatment.
TOP-333
bottom of page